June 8, 2013, Dallas, Texas
The healthcare delivery landscape in the United States continues to shift as reforms mandated in 2010 by the Patient Protection and Affordable Care Act become manifest. The Center for Medicare & Medicaid Innovation, accountable care organizations, and the health insurance marketplace (or exchange), slated to begin in January 2014, will continue to impact the practice of medicine. Today’s physicians are tasked with learning about and complying with new data collection requirements, clinical practice pathways, and healthcare delivery models.
For urologists who manage prostate cancer, these sweeping healthcare policy changes coincide with remarkable technological and therapeutic innovations. Continual enhancements in prostate surgery, radiation delivery techniques, diagnostic imaging, and pharmaceuticals have significantly improved outcomes for men with prostate cancer. Together, however, the combination of comprehensive healthcare reforms and fast-paced clinical advances has resulted in a challenging environment for urologists. To continue to provide state-of-the-art, quality-driven, and cost-effective care for their patients with prostate cancer, these specialists must reconsider both clinical and economic aspects of their practices.
In June 2013, the Prostate Cancer Steering Committee met in Dallas, Texas, to explore ways in which urology practices are addressing today’s business and healthcare environment challenges, including the viability of implementing integrated and comprehensive cancer care services. The Steering Committee also deliberated on various trends in the clinical management of men with prostate cancer, focusing primarily on the diagnosis of metastatic prostate cancer and the incorporation of newer therapies to treat these patients.